EPISODE · Dec 24, 2018 · 9 MIN
Walmsley's GSK gamble
from FT News in Focus
GlaxoSmithKline is combining its consumer health business with that of US rival Pfizer, paving the way for a separation of its core consumer and pharmaceuticals businesses within three years. Chief executive Emma Walmsley is betting the cash generated by the enlarged consumer unit will fund further investment in the pharmaceutical business ahead of the demerger. Matthew Vincent is joined by Sarah Neville and Arash Massoudi to discuss the merits of the deal and its implications for the health and pharmaceuticals markets.Contributors: Naomi Rovnick, FT Live reporter, Matthew Vincent, Lombard columnist, Sarah Neville, global pharmaceuticals editor and Arash Massoudi, corporate finance and deals editor. Producer: Sam Westran Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
GlaxoSmithKline is combining its consumer health business with that of US rival Pfizer, paving the way for a separation of its core consumer and pharmaceuticals businesses within three years. Chief executive Emma Walmsley is betting the cash generated by the enlarged consumer unit will fund further investment in the pharmaceutical business ahead of the demerger. Matthew Vincent is joined by Sarah Neville and Arash Massoudi to discuss the merits of the deal and its implications for the health and pharmaceuticals markets.Contributors: Naomi Rovnick, FT Live reporter, Matthew Vincent, Lombard columnist, Sarah Neville, global pharmaceuticals editor and Arash Massoudi, corporate finance and deals editor. Producer: Sam Westran Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Walmsley's GSK gamble
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m